Navigation Links
iPierian Expands Leadership Team With Experienced Business Development and Intellectual Property Executives
Date:9/30/2010

SOUTH SAN FRANCISCO, Calif., Sept. 30 /PRNewswire/ -- iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced that it has appointed Michael P. Smith as Vice President, Business Development and Wayne Montgomery, J.D.,  as Vice President, Legal Affairs and Intellectual Property.

"Mike brings to iPierian a breadth of strategic and transactional experience at both small and large companies.  This will be invaluable as we enter therapeutic drug discovery collaborations with global biopharma companies, to achieve our goal of using iPSC technology to transform drug discovery and development," said Michael C. Venuti, Ph.D., CEO of iPierian.  "Wayne has built and executed IP strategies spanning broad technology platforms to small molecule compositions.  As we advance our foundational intellectual property for iPSC drug discovery, as well as move our lead therapeutic programs forward, his leadership will be a key part of creating value for iPierian. We are delighted to welcome these two executives with such strong experience and track records."

Michael Smith most recently served as Head of Business Development and Chief Financial Officer for Memory Pharmaceuticals, which was acquired by Roche.  His experience includes a broad range of strategic transactions and initiatives including product and technology licenses, R&D collaborations, joint ventures, M&A, and strategic and portfolio planning.  Prior to Memory, Mr. Smith served as Vice President of Business Development for QLT Inc., where he was responsible for all business development activities and corporate strategy.  From 1998 to 2004, he was with Chiron Corporation most recently as Director of Corporate Development and held positions in several functions including strategic planning, corporate finance and commercial sales.  Mr. Smith holds a B.S. from the University of Virginia and an M.B.A. from the University of California, Berkeley.

Wayne Montgomery, J.D., joins iPierian with over twenty years of experience as an intellectual property law attorney in the biopharmaceutical industry.  He most recently served as Vice President of Patents at Exelixis.  Previously, he served as Vice President of Intellectual Property at Nektar Therapeutics.  He held the position of Vice President, Assistant General Counsel & Chief Patent Counsel at Axys Pharmaceuticals prior to its acquisition by Celera, and subsequently Vice President of Intellectual Property at Celera Genomics.  Mr. Montgomery began his legal career with Syntex Legal Affairs.  Prior to entering the legal profession, he served as a pharmacologist with Syntex Research.  He received a J.D. degree from Santa Clara University School of Law and undergraduate degrees in biochemistry and pharmacology from the University of California, Santa Barbara.

About iPierian

iPierian is the leading biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPSC) technology and directed differentiation of patient cells for the discovery and development of new therapeutics. iPierian's approach places the patient at the forefront of the drug discovery process in order to reduce drug development time and increase the probability of success by using precise human disease models to develop proprietary small molecule or biologic therapeutics. The initial therapeutic focus of the company is neurodegenerative diseases, including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease, in addition to a broad therapeutic area program intended for partnering in metabolic disease.

The company's Scientific Advisory Board (SAB) is comprised of leading researchers and authorities in the stem cell field, including individual investigators from the Harvard Stem Cell Institute, The Gladstone Institute and The University of California, San Francisco.  Our scientific founders are George Q. Daley, M.D., Ph.D., Douglas A. Melton, Ph.D., and Lee L. Rubin, Ph.D. all of the Harvard Stem Cell Institute, and Deepak Srivastava, M.D., of the Gladstone Institute and UCSF.

iPierian is located in South San Francisco, California. For more information, please visit www.ipierian.com.


'/>"/>
SOURCE iPierian, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FierceBiotech Names iPierian as One of the Fierce 15 Biotech Companies of 2010
2. iPierian Awarded Basic Biology Grant by California Institute of Regenerative Medicine to Study Cellular Reprogramming
3. iPierian to Collaborate With Johns Hopkins University on $3.7 Million NIH Grand Opportunities Grant
4. iPierian Appoints Dr. Matthew J. Plunkett as Chief Financial Officer
5. iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
6. Vital Therapies Expands SILVER Trial to Saudi Arabia
7. Launch of Two New Platforms for Microplate Analysis Expands Reader Portfolio and Ensures Molecular Devices Readers Meet all Combinations of Customer Needs
8. China BCT Further Expands its Footprint by Opening 12 New Retail Pharmaceutical Stores
9. Advanced Life Sciences Expands Antibiotic Pipeline
10. London Genetics Expands its Senior Advisory Team
11. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... YORK , Feb. 11, 2016  Bioethics International, a ... medicines are researched, developed, marketed and made accessible to patients ... BMJ Open had named the publication of the ... 2015. The publication is also featured as one of ... in the last year that are most frequently read. ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... dedicated to delivering cutting-edge information focused on the development and manufacture of ... become a premier sponsor of the 2016 BioProcess International Awards – Recognizing ...
(Date:2/11/2016)...   BioInformant announces the February 2016 release ... Opportunities, Tools, and Technologies – Market Size, Segments, Trends, ... The first and only market ... BioInformant has more than a decade of historical information ... stem cell type. This powerful 175 page global strategic ...
(Date:2/11/2016)... ... 2016 , ... Global Stem Cells Group, has ... The new facility will provide advanced protocols and state-of-the-art techniques in cellular medicine, ... , The new GSCG clinic is headed by four prominent Ecuadorian physicians, including ...
Breaking Biology Technology:
(Date:2/1/2016)... Canada , February 1, 2016 ... technological advancements to drive global touchfree intuitive gesture control ... --> Rising sales of consumer electronics coupled ... gesture control market size through ... consumer electronics coupled with new technological advancements to drive ...
(Date:1/25/2016)... 2016   Unisys Corporation (NYSE: UIS ) today ... (JFK) International Airport, New York City , to ... attempting to enter the United States using ... pilot testing of the system at Dulles last year. ... JFK during January 2016. --> pilot testing of ...
(Date:1/20/2016)... 20, 2016 A market that just keeps ... from the explosion in genomics knowledge. Learn all about ... A range of dynamic trends are pushing market growth ... medicine - pharmacogenomics - pathogen evolution - next generation ... - greater understanding of the role of genetic material ...
Breaking Biology News(10 mins):